^
    Back
    Association details:
    Biomarker:EGFR exon 19 deletion + PD-L1 overexpression
    Cancer:Lung Adenocarcinoma
    Drug:gefitinib (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    Source:
    Front Oncol
    Title:

    Case Report: Re-Sensitization to Gefitinib in Lung Adenocarcinoma Harboring EGFR Mutation and High PD-L1 Expression After Immunotherapy Resistance, Which Finally Transform Into Small Cell Carcinoma

    Published date:
    06/24/2021
    Excerpt:
    A 43-year-old male Asian non-smoker underwent surgical resection of lung mass, with a diagnosis of stage IIA lung adenocarcinoma (pT2bN0M0) harboring an EGFR del-19 mutation and high PD-L1 (80.9%) expression...gefitinib was given for 21 months until clinical resistance when a new nodule in the left residual lung appeared.
    DOI:
    10.3389/fonc.2021.661034